Baxter International Management

Management criteria checks 1/4

Baxter International's CEO is Joe Almeida, appointed in Jan 2016, has a tenure of 8.25 years. total yearly compensation is $13.79M, comprised of 9.4% salary and 90.6% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth MX$392.15M. The average tenure of the management team and the board of directors is 1.9 years and 4.2 years respectively.

Key information

Joe Almeida

Chief executive officer

US$13.8m

Total compensation

CEO salary percentage	9.4%
CEO tenure	8.3yrs
CEO ownership	0.1%
Management average tenure	1.9yrs
Board average tenure	4.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Joe Almeida's remuneration changed compared to Baxter International's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$14m	US$1m	-US$76m
Sep 30 2023	n/a	n/a	US$225m
Jun 30 2023	n/a	n/a	-US$3b
Mar 31 2023	n/a	n/a	-US$2b
Dec 31 2022	US$14m	US$1m	-US$3b
Sep 30 2022	n/a	n/a	-US$3b
Jun 30 2022	n/a	n/a	US$876m
Mar 31 2022	n/a	n/a	US$992m
Dec 31 2021	US$16m	US$1m	US$1b
Sep 30 2021	n/a	n/a	US$1b
Jun 30 2021	n/a	n/a	US$1b
Mar 31 2021	n/a	n/a	US$1b
Dec 31 2020	US$16m	US$1m	US$1b
Sep 30 2020	n/a	n/a	US$911m
Jun 30 2020	n/a	n/a	US$924m
Mar 31 2020	n/a	n/a	US$991m
Dec 31 2019	US$14m	US$1m	US$1b
Sep 30 2019	n/a	n/a	US$1b
Jun 30 2019	n/a	n/a	US$1b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$16m	US$1m	US$2b
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$795m
Mar 31 2018	n/a	n/a	US$840m
Dec 31 2017	US$15m	US$1m	US$609m

Compensation vs Market: Joe's total compensation ($USD13.79M) is above average for companies of similar size in the MX market ($USD5.98M).

Compensation vs Earnings: Joe's compensation has increased whilst the company is unprofitable.

CEO

Joe Almeida (61 yo)

8.3yrs

Tenure

US$13,786,671

Compensation

Mr. Jose E. Almeida, also known as Joe, has been the Chairman of the Board and Chief Executive Officer of Baxter International Inc. since January 1, 2016 and serves as its President since January 01, 2016....

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jose Almeida	Chairman of the Board	8.3yrs	US$13.79m	0.11% $ 394.2m
Joel Grade	Executive VP & CFO	less than a year	US$5.37m	0% $ 0
Heather Knight	Executive VP & Group President of Medical Products and Therapies	1.1yrs	US$4.86m	0.031% $ 110.9m
Alok Sonig	Executive VP & Group President of Pharmaceuticals	1.8yrs	US$3.87m	0.0016% $ 5.5m
Christopher Toth	Executive VP & Group President of Kidney Care	less than a year	US$9.64m	0% $ 0
Tobi Karchmer	Senior VP and Chief Medical & Scientific Officer	1.3yrs	no data	no data
Clare Trachtman	Vice President of Investor Relations	no data	no data	no data
David Rosenbloom	Executive VP & General Counsel	2yrs	US$5.66m	0.0014% $ 4.9m
Stacey Eisen	?Senior Vice President	no data	no data	no data
Jeanne Mason	?Executive VP & Chief Human Resources Officer	6.9yrs	US$4.14m	0.037% $ 130.4m
James Borzi	Executive VP & Chief Supply Chain Officer	4.3yrs	no data	0.0030% $ 10.5m
Reazur Rasul	Executive VP & Group President of Healthcare Systems and Technologies	2.3yrs	no data	0.021% $ 75.5m

1.9yrs

Average Tenure

56yo

Average Age

Experienced Management: BAX *'s management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Jose Almeida	Chairman of the Board	8.3yrs	US$13.79m	0.11% $ 394.2m
Stephen Rusckowski	Independent Director	less than a year	US$197.82k	0.00061% $ 2.1m
Robert Parkinson	Chairman Emeritus	8.3yrs	US$17.88m	no data
Peter Wilver	Independent Director	1.9yrs	US$349.64k	0.0014% $ 5.0m
Stephen Newman Oesterle	Independent Director	7.2yrs	US$373.98k	0.0043% $ 15.1m
Patricia Morrison	Independent Director	5.2yrs	US$364.98k	0.0030% $ 10.6m
Nancy Schlichting	Independent Director	2.3yrs	US$363.00k	0.00015% $ 528.5k
Catherine Smith	Independent Director	7.3yrs	US$367.31k	0.0032% $ 11.4m
David Shafer	Lead Independent Director	1.9yrs	US$382.31k	0.0014% $ 5.0m
David Wilkes	Independent Director	3.2yrs	US$357.00k	0.00054% $ 1.9m
William Ampofo	Independent Director	less than a year	US$226.35k	0.00076% $ 2.7m
Amy Wendell	Independent Director	5.2yrs	US$352.98k	no data

4.2yrs

Average Tenure

65yo

Average Age

Experienced Board: BAX *'s board of directors are considered experienced (4.2 years average tenure).

Baxter International Management

Management criteria checks 1/4

Key information

Recent management updates

High number of new directors

Baxter International Inc., Annual General Meeting, May 07, 2024

Baxter International Inc., Annual General Meeting, May 07, 2024

High number of new directors

Baxter International Inc. Announces Management Appointments

Baxter International Inc. Announces Board Changes

Recent updates

Baxter International Inc. Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S

High number of new directors

Baxter International Inc. Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy

Baxter International Inc., Annual General Meeting, May 07, 2024

Baxter International Inc., Annual General Meeting, May 07, 2024

Upcoming dividend of US$0.29 per share

Fourth quarter dividend of US$0.29 announced

Baxter International Inc. Declares Quarterly Dividend, Payable on April 1, 2024

High number of new directors

Baxter International Inc. Provides Sales Guidance for the First Quarter and Full Year 2024

Baxter International Inc. Announces the Completion of the First Phase of Its Intravenous (IV) Bag Recycling Program Pilot

Baxter International Inc. Declares Quarterly Dividend, Payable on January 2, 2024

Baxter International Inc. Highlights New Data At Kidney Week Indicating Sharesource Is Associated with A 77% Lower Risk of Home Dialysis Technique Failure

Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Year 2023

Baxter International Inc. Digital Image Capture Capability for PanOptic Plus Ophthalmoscope

Baxter International Inc. Announces Management Appointments

Levi & Korsinsky Notifies Baxter International Inc. Investors of A Class Action Lawsuit and Upcoming Deadline

Baxter International Inc. Announces Board Changes

The Klein Law Firm Announces That A Class Action Complaint Has Been Filed on Behalf of Shareholders of Baxter International Inc. Alleging That the Company Violated Federal Securities Laws

Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.36 profit in 2Q 2022)

Baxter International Inc. Launches PERCLOT Absorbable Hemostatic Powder

High number of new directors

Baxter International Inc. Declares Quarterly Cash Dividend, Payable on October 2, 2023

Rosen Law Firm Announces the Filing of Class Action Lawsuit on Behalf of Purchasers of Securities of Baxter International Inc

Baxter International Inc. Appoints William Ampofo to Its Board of Directors

Baxter International Inc.(NYSE:BAX) dropped from Russell 1000 Growth Index

Upcoming dividend of US$0.29 per share at 2.8% yield

Baxter International Inc. Announces James K. Saccaro Notifies to Resign as Executive Vice President, Effective as of May 31, 2023

Advent International Corporation and Warburg Pincus LLC signed a definitive agreement to acquire Baxter Pharmaceutical Solutions LLC from Baxter International Inc. (NYSE:BAX) for $4.3 billion.

Baxter International Inc. Selects Chris Toth to Be Chief Executive Officer of the Company’s Planned Spinoff of Its Renal Care and Acute Therapies Businesses

First quarter 2023 earnings released: EPS: US$0.087 (vs US$0.14 in 1Q 2022)

Baxter International Inc. Announces Management Changes

Baxter International Inc. Declares Quarterly Dividend, Payable on April 3, 2023

Full year 2022 earnings released: US$4.83 loss per share (vs US$2.56 profit in FY 2021)

Baxter International Inc. Reports Goodwill Impairment for the Fourth Quarter Ended December 31, 2022

Baxter International Inc. Announces Resignation of Giuseppe Accogli as Executive Vice President and Chief Operating Officer

Baxter Introduces ExactaMix Pro Automated Compounder

Upcoming dividend of US$0.29 per share

Baxter International Inc. Declares Quarterly Cash Dividend, Payable on January 3, 2023

Baxter International Inc. Highlights New Home Dialysis and HDX Therapy Data in 14 Clinical Presentations At Kidney Week 2022

Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Third quarter 2022 earnings released: US$5.83 loss per share (vs US$0.90 profit in 3Q 2021)

Baxter International Inc. to Report Q3, 2022 Results on Oct 27, 2022

Baxter International Inc. Announces U.S. FDA Clearance of Novum IQ Syringe Infusion Pump with Dose IQ Safety Software

Upcoming dividend of US$0.29 per share

Baxter International Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2022

Second quarter 2022 earnings released: EPS: US$0.25 (vs US$0.59 in 2Q 2021)

Baxter International Inc. Announces Executive Changes

Baxter International Inc. Declares Quarterly Dividend, Payable on October 3, 2022

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age